MedTrace Logo

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

NCT06885021 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 780

Last updated 2025-03-19

No results posted yet for this study

Summary

A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Conditions

  • Overweight and Obesity

Interventions

DRUG

HDM1002 200mg, oral, once daily, 52 weeks

HDM1002 200mg, oral, once daily, 52 weeks

DRUG

HDM1002 400mg, oral, once daily, 52 weeks

HDM1002 400mg, oral, once daily, 52 weeks

DRUG

HDM1002 placebo, oral, once daily, 52 weeks

HDM1002 placebo, oral, once daily, 52 weeks

Sponsors & Collaborators

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-28
Primary Completion
2026-05-30
Completion
2026-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06885021 on ClinicalTrials.gov